Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | STK17B | O94768 | 1/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.35 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25433834 | 0.87 | CACNA1H (0.43) | CACNA1HCACNA1BCACNA1CSMN1; SMN2KDM4A | |
| SCHEMBL30552716 | 0.87 | CACNA1H (0.43) | CACNA1HCACNA1BCACNA1CSMN1; SMN2KDM4A | |
| SCHEMBL27151020 | 0.83 | RAB9A (0.41) | SMN1; SMN2LMNARAB9AMETTL3METTL14 | |
| SCHEMBL30632885 | 0.81 | SMN1; SMN2 (0.48) | CACNA1HCACNA1BCACNA1CSMN1; SMN2KDM4A | |
| SCHEMBL23478663 | 0.81 | SMN1; SMN2 (0.48) | CACNA1HCACNA1BCACNA1CSMN1; SMN2KDM4A | |
| SCHEMBL19964841 | 0.78 | SMN1; SMN2 (0.45) | CACNA1HCACNA1BCACNA1CSMN1; SMN2KDM4A | |
| SCHEMBL30920730 | 0.78 | NQO2 (0.48) | CACNA1HCACNA1BCACNA1CSMN1; SMN2KDM4A | |
| SCHEMBL25155252 | 0.77 | SMN1; SMN2 (0.44) | CACNA1HCACNA1BCACNA1CSMN1; SMN2KDM4A | |
| SCHEMBL25677972 | 0.77 | KDM4A (0.54) | CACNA1HCACNA1BCACNA1CSMN1; SMN2KDM4A | |
| SCHEMBL30469092 | 0.77 | KDM4A (0.54) | CACNA1HCACNA1BCACNA1CSMN1; SMN2KDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | CACNA1H 2691/4885CACNA1B 2526/4885CACNA1C 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.